Skip to content
Research/Longevity Diagnostics/Extended Serum Biomarker and Hormonal Panel

Extended Serum Biomarker and Hormonal Panel

The Extended Serum Biomarker and Hormonal Panel is a comprehensive diagnostic tool that measures various biomarkers and hormones in the blood to assess overall health and identify potential longevity-related issues. By providing detailed insights into metabolic, hormonal, and inflammatory states, this panel aids in personalized health optimization and early detection of age-related conditions.

Intelligence Profile

Science

The "Extended Serum Biomarker and Hormonal Panel" likely functions by monitoring various biomarkers and hormones to assess physiological states or disease conditions. While the specific mechanism of the panel is not detailed in the available evidence, several related studies provide insights into the potential roles of different biomarkers.

  1. Oxidative Stress and Inflammatory Markers: The evidence suggests that biomarkers such as Serum Amyloid A (SAA) and tumor necrosis factor (TNF) play crucial roles in inflammatory responses. For instance, SAA is associated with inflammatory processes in HIV-related infections and correlated with other inflammatory markers. TNF and lipid peroxide levels, which decrease with interventions like dietary changes (e.g., strawberry consumption), indicate inflammation and oxidative stress levels.

  2. Liver Function and Atherogenesis: High-normal levels of alanine aminotransferase (ALT) are linked with atherogenesis risk factors, suggesting its role in liver function monitoring as part of the biomarker panel, particularly in relation to metabolic and cardiovascular health.

  3. Kidney Injury and Cardio-Renal Syndrome: Neutrophil gelatinase-associated lipocalin (NGAL) serves as a marker for early diagnosis of acute kidney injury and cardio-renal syndrome. This emphasizes the panel’s utility in identifying renal complications.

  4. Hormonal and Metabolic Conditions: Though details on hormonal panel components are lacking, clinical trials like COMPASS-pedPCOS focus on liver steatosis associated with hormonal imbalances (e.g., in PCOS), highlighting potential targets for this panel.

The panel seems to integrate diverse biomarkers to provide comprehensive health insights, covering aspects from inflammation and oxidative stress to organ function and hormonal balance. However, specific interactions at a molecular level are not detailed in the evidence available.

Disclaimer: This content is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.